Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. 1.

    Hermine O, Lefrère F, Bronowicki J-P, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C Virus Infection. N Engl J Med. 2002.

  2. 2.

    Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005.

  3. 3.

    Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005.

  4. 4.

    Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, et al. From hepatitis C virus infection to B-cell lymphoma. Ann. Oncol. 2018.

  5. 5.

    Webster DP, Klenerman P, Dusheiko GM. Lancet seminar—hepatitis C. Lancet. 2015.

  6. 6.

    Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver Int. 2016.

  7. 7.

    Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016.

  8. 8.

    Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun. Rev. 2017.

  9. 9.

    Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJM, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014.

  10. 10.

    Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell nonHodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015.

  11. 11.

    Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007.

  12. 12.

    Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V. et al. Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116:343–53.

    CAS  Article  Google Scholar 

  13. 13.

    Torres HA, Pundhir P, Mallet V Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 2019.

  14. 14.

    Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer. 2001.

  15. 15.

    Jonasch E. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2004.

Download references


The research leading to these results has received funding from AIRC under IG 2017—ID. 20767 project—P.I. Luca Arcaini and from “Ricerca Corrente Fondazione IRCCS Policlinico San Matteo”—P.I. Luca Arcaini. The ANRS-CO22 HEPATHER cohort was sponsored and funded by ANRS (France REcherche Nord & Sud Sida-HIV Hépatites). The sponsor has not participated in the statistical analysis and interpretation of data, in the writing the manuscript, and in the decision to submit the work for publication.

Author information




MF, LA, OH, and CB designed and supervised the overall conduction of the study; VVF, LA, and MF analyzed the data; MF and LA wrote the paper; M.F. and LA collected the data; MF, CB, CV, HF, MGo, MV, AP, HAT, JPO, RR, FZ, LR, MMe, CD, CA, FP, MGe, AF, MP, LN, SR, AF, MMi, EC, ID, RB, OH, and LA enrolled and cared for the patients; MF, CB, OH, and LA. reviewed the paper and all authors approved the final paper.

Corresponding author

Correspondence to Luca Arcaini.

Ethics declarations

Conflict of interest

LA received advisory honoraria from Bayer, Celgene, Gilead, Roche, Sandoz, Verastem and research support from Gilead. HAT is or has been the principal investigator for research grants from Gilead Sciences, Merck & Co., Inc., and Vertex Pharmaceuticals, with all funds paid to MD Anderson. HAT also is or has been a paid scientific advisor for Gilead Sciences, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Vertex Pharmaceuticals, Genentech, Novartis, Astellas Pharma, Pfizer Inc., and Theravance Biopharma, Inc.; the terms of these arrangements are being managed by MD Anderson in accordance with its conflict of interest policies. AP received advisory honoraria from Roche, Merck, Pfyzer, Sandoz, Takeda.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Frigeni, M., Besson, C., Visco, C. et al. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia 34, 1462–1466 (2020).

Download citation

Further reading


Quick links